

SAMPLE

Cancer & Antibody Conjugates (Drug / Radionuclide)

Patent Landscape
Analysis

December 2025

TABLE OF CONTENTS

<u>INTRODUCTION</u>	<u>6</u>	<u>PATENT SEGMENTATION</u>	<u>37</u>
<ul style="list-style-type: none">- What are antibody conjugates?- First approvals, opportunities & challenges in oncology- Scope of the report- Patent search, selection and analysis- Search strategy- Excel database- Reading guide		<ul style="list-style-type: none">- Definition- Main assignees by technology- Antibody moiety- Linker- Payload moiety	
<u>EXECUTIVE SUMMARY</u>	<u>14</u>	<u>IP PROFILE OF KEY PLAYERS</u>	<u>57</u>
<u>PATENT LANDSCAPE OVERVIEW</u>	<u>18</u>	<p>Overview, key patents & clinical trials of:</p> <ul style="list-style-type: none">- Pfizer- Genentech- Roche- AbbVie- AstraZeneca- Gilead	
<ul style="list-style-type: none">- Time evolution of patent publications- Ranking of most prolific patent applicants- Current legal status of the main players- Patent legal status of the corpus- Mapping of main current IP holders- Time evolution of main patent assignees		<u>METHODOLOGY</u>	<u>86</u>
<u>NEWCOMERS</u>	<u>26</u>	<ul style="list-style-type: none">- Patent search, selection and analysis- Terminologies- Key IP players- Key patents	
<ul style="list-style-type: none">- Chinese companies- Other companies		<u>KNOWMADE PRESENTATION</u>	<u>94</u>
<u>IP POSITION OF MAIN APPLICANTS</u>	<u>30</u>	<u>CONTACT</u>	<u>99</u>
<ul style="list-style-type: none">- IP leadership of patent applicants- IP prior art blocking potential of patent applicants- Patent citation- Strength index of patent portfolios			

THE AUTHORS



PhD Fabienne Massa

Fabienne works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular and Cellular Biology from the IPMC (Sophia Antipolis, France). She also holds a Master of Business Management from IAE (Nice, France) and she previously worked in the pharmaceutical industry.

Contact: fabienne.massa@knowmade.fr



PhD Brice Sagot

CTO and co-founder of KnowMade. He leads the Biotechnology and Life Sciences department. He holds a PhD in Molecular Biology from the University of Nice Sophia-Antipolis (France).

Contact: brice.sagot@knowmade.fr

ONE-HOUR PRESENTATION

The author of the report is available to address any questions you may have.

A **one-hour online presentation** of the report is included with your purchase. This session offers the opportunity for a direct interaction with the author, including a presentation of the results and a dedicated Q&A session.

Feel free to contact the author to schedule a meeting.



KNOWMADE is a technology intelligence and IP strategy consulting company specialized in analyzing patents and scientific publications. The company assists innovative companies, investors, and R&D organizations to understand the competitive landscape, tracking technological developments, reducing uncertainties, and identifying opportunities and risks related to innovations and patents. Our highly qualified analysts transform patent information and scientific literature into actionable insights, delivering high value-added reports for decision-makers working in R&D, Intellectual Property, and Innovation Strategy.

INTRODUCTION

Scope of the report

- This report provides a detailed picture of the patent landscape for **Antibody-Drug Conjugates & Cancer**.
- This report covers **patents published worldwide up to July 2025**.
- We have selected and analyzed about **+3760 patent families** relevant to the scope of this report.

You want a deeper analysis on technologies or companies

Contact us for a custom report



Included in the report

- ✓ All cancer: hematological cancers (e.g., leukemia, lymphoma), solid cancers (e.g., prostate cancer, melanoma) and virus-induced cancers (e.g., HPV, EBV)
- ✓ All antibody formats: humanized, fully human, IgGs, bispecific, trispecific, crossMab, etc.
- ✓ All antigens / epitopes recognition: tumor antigens (e.g., PSMA, BRCA), immune checkpoints (e.g., PD-1, CTLA-4) and immune cell receptors (e.g., CD3, CD28)

Not included in the report

- X Other therapeutic applications: virus or bacteria infection, diabetes, cardiovascular pathology, etc.
- X Other antibody-conjugates: oligonucleotide , antibiotic, degrader, aptamer, etc.

INTRODUCTION

Key features of the report

- **Excel database** comprising all analyzed patents of the report is provided.
- This **patent database** allows multi-criteria searches, including:
 - Patent publication number
 - Hyperlinks to the original documents
 - Priority date
 - Title
 - Abstract
 - Patent assignees
 - Technical segmentation
 - Legal status for each member of the patent family.
- The findings, interpretations and conclusions expressed in this report are entirely those of Knowmade and may not constitute or imply endorsement by a decision-making body such as a court of law or a patent office. Any assessment of the effect or scope of pending applications or granted patents reflects our own views and these are not necessarily those of a Patent Attorney. Should confirmation of our assessment in this respect be required, we recommend that you seek the advice of a national Patent Attorney.



Patent Landscape Overview

Patent assignees, IP dynamics, patent legal status, patent geographical coverage

SAMPLE


PATENT LANDSCAPE OVERVIEW

Time Evolution of Patent Publications




PATENT LANDSCAPE OVERVIEW

Main Patent Assignees




PATENT LANDSCAPE OVERVIEW

Mapping of Main Current Patent Holders



PATENT LANDSCAPE OVERVIEW

Time Evolution of Main Patent Assignees



Patent Landscape Overview

Identify main newcomers

SAMPLE

IP INDUSTRIAL NEWCOMERS

Headquarters location : China

Chinese Assignees		
ANHUI JINBAIAO BIOTECHNOLOGY	HANGZHOU SEEHE BIOTECHNOLOGY	SHANGHAI HUAHE PHARMACEUTICAL

IP INDUSTRIAL NEWCOMERS

Overview

In this study, companies that published their first patent in 2024 or later are considered as IP newcomers. The analysis identified **147 industrial IP newcomers**, primarily located in Asia (table opposite).

Since 2024, 147 industrial IP newcomers entered the antibody-conjugate field, with a clearly asymmetric geographical distribution that mirrors current R&D dynamics in ADCs and radioimmunoconjugates. Most new players are located in Asia, and China alone accounts for more than half of them (78 newcomers), ahead of Korea (21), Singapore (13) and Taiwan (12). This strong Asian footprint is consistent with the rapid expansion of ADC pipelines, clinical trials and partnering activity reported in the region, particularly in China, which has emerged as a major hub for "enhanced" antibody therapeutics and next-generation ADCs.

North America and Europe remain important but comparatively less dynamic sources of new industrial firms, with 11 newcomers identified in the USA and 12 in European countries, while Canada and Australia each contribute a single new entrant. This suggests that, although ADCs and radioimmunoconjugate approaches are now firmly established as key modalities in oncology in Western markets, much of the incremental competitive pressure and IP crowding is currently being driven by Asian companies.

Overall, the map highlights a shift toward an Asia-centric innovation landscape for antibody conjugates. For established pharma and biotech companies, this reinforces the need to monitor Asian IP, anticipate freedom-to-operate issues in key targets and payload/linker technologies, and consider strategic collaborations or in-licensing with emerging regional players to secure access to this rapidly expanding ecosystem.

Geographic area	Newcomer #
China	78
Korea	21
Singapore	13
Taiwan	12
USA	11
Europe	12
Australia	1
Canada	1

Geographical distribution of patent publications



- AI JUNSHI BIOTECHNOLOGY
- EDENOVA BIOMEDICAL TECHN
- U PHARMACEUTICAL R&D CENTER
- ENJING PHARMACEUTICAL TECH
- HAI SHUANGGE INDUSTRY
- HAI TIANGLING BIOMEDICAL
- IGHAI UBIQUIT BIOTECH
- NGHAI VISONPHARMA
- DMING HELIAN BIOTECHNOLOGY
- N GENUINE BIOTECHNOLOGY
- ZHEN ZEAN BIOMEDICAL
- MAB BIOTHERAPEUTICS
- NSHINE LAKE PHARMA
- KINTOR PHARMACEUTICALS
- GSI SHANGHAI BIOMEDICAL
- INMED LIFE SCIENCE
- TOT BIOPHARM
- HARMACEUTICALS SHANGHAI
- ID BIOSCIENCE SHANGHAI
- EL SHANGHAI BIOPHARMA
- VELAVIGO BIO
- IOPHARMACEUTICAL SUZHOU
- IGHAI BIOLOG MED SC & TECH
- INACHENG BIOTECHNOLOGY
- ON BIOPHARMA INSTITUTE

/ Radionuclide) – Patent Landscape Analysis - Ref. : KM25XXX
© 2025 All rights reserved | www.knowmade.com

28


27

Patent Portfolios Benchmarking: Beyond the Quantity

Who has the best patent portfolio?

IP POSITION OF PATENT APPLICANTS

IP Leadership of Patent Assignees



IP POSITION OF PATENT APPLICANTS

Prior Art Blocking Potential




Patent portfolios with a high prior art IP blocking potential are relevant in evaluating the patentability of patent applications filed afterwards. Old patent families are more likely to receive a high number of citations from subsequent applications. Therefore, well-cited patent families are likely to be relevant prior art “blocking” the patenting activity of competitors (i.e., novelty and inventiveness assessment).

IP POSITION OF PATENT APPLICANTS

Strength Index (2/2)

Strength Index vs Number of patent families



- Genentech - Roche** retains the strongest overall position with the highest Strength Index and a high citation impact. Despite having fewer families than Pfizer, its citation density and technological influence are unparalleled. This confirms its pioneering and central role in ADC technologies, outside HER2-related platforms and conjugation chemistries.
- Pfizer** ranks second but holds the largest portfolio in volume (270 patent families). Its Strength Index per family is slightly lower than Genentech-Roche's, and still indicates broadly impactful, internationally protected, and enforceable patents. Pfizer thus combines portfolio size and quality making it one of the most strategically powerful IP players.
- Gilead** follows with a very high technological impact (ROI) and one of the highest citation rates per family—a clear reflection of the immunotoxicology (ITX)/ADC portfolio. Despite a smaller number of families, its patents are frequently cited and influential, confirming its strong entrance into the ADC field through acquisition of Cell Signalling.
- British Biotech Squibb (BBS)**, although ranked lower in total Strength Index, stands out with an exceptionally high Strength Index per family and a very strong technological impact factor. This suggests a smaller but extremely influential portfolio, with patents that act as major prior art within ADC R&D (notably around payload chemistry and antibody engineering).

- Genentech - Roche** and **Gilead** show the highest blocking potential, with very large portfolios extensively cited by numerous organizations. Patent portfolios are highly cited in the field of ADC and cancer treatment, receiving various citations from Roche, Novartis, AbbVie, Pfizer, AstraZeneca and Amgen. Regarding Gilead, most of patent families (~90) have been filed by immunomedics, acquired by Gilead in 2020.
- Pfizer**, **British Biotech Squibb (BBS)**, and **AbbVie** also demonstrate high technological impact, reflecting diversified ADC portfolios that attract a large number of external citations. These actors combine both breadth (many families cited) and depth (high citation rate per family).
- Overall, the figure shows that a small number of players hold strong IP leverage, capable of constraining the patenting space for emerging companies through their prior art coverage.
- This concentration of blocking potential reinforces the importance of freedom-to-operate (FTO) assessments and licensing strategies for new entrants developing ADC candidates.

Patent Segmentation

What are the key IP players for each segments?

Patent families were segmented into the following categories:

- 1. Antibody Segment:** Liquid Cancer; Liquid Cancer Only; Solid Cancer; Solid Cancer Only.
- 2. Linker Segment:** Cleavable; Uncleavable.
- 3. Payload Segment:** Drugs such as microtubule inhibitors (e.g., auristatins, maytansinoids), DNA-damaging agents (e.g., calicheamicin), and topoisomerase I inhibitors (e.g., deruxtecan); Radioisotopes such as β - or α -emitting radionuclides (e.g., yttrium-90, lutetium-177, actinium-225) to deliver localized ionizing radiation.

PATENT SEGMENTATION Antibody - Liquid cancer: Overview



PATENT SEGMENTATION Overview: definition

To better characterize innovation trends and R&D strategies in the ADC field, the patent language has been segmented into three main technological components: antibody, linker, and payload. Each component plays a crucial role in defining the specificity, stability, and therapeutic profile of an ADC.

- 1. Antibody Segment:** Antibodies determine the biological target and clinical indication of the conjugate.
 - Antibody - Liquid Cancer:** ADCs developed for hematologic malignancies. These targets are typically cell-surface antigens with high and/or homogeneous expression. - **Liquid Cancer Only:** patent families describing ADC for hematologic cancers without crossover to solid tumor indications (claims).
 - Antibody - Solid Cancer:** ADCs targeting tumor-associated antigens expressed in solid malignancies. These programs face additional pharmacokinetic and tumor-penetration challenges. - **Solid Cancer Only:** patent families describing ADC for solid cancer without crossover to liquid cancer (claims).
- 2. Linker Segment:** The linker is a chemical bridge connecting the Ab and the payload. Its design determines stability and controlled release at the tumor site.
 - Cleavable Linkers:** Engineered to release the payload upon exposure to intracellular conditions (e.g., pH change, enzymatic cleavage, or reduction).
 - Uncleavable Linkers:** Designed for maximal plasma stability. The payload is released only after complete proteolytic degradation of the antibody within the lysosome, improving selectivity but limiting diffusion.
- 3. Payload Segment:** The payload defines the mechanism of cytotoxicity and largely drives clinical efficacy and toxicity.
 - Payload - Drugs:** Include small molecules such as microtubule inhibitors (e.g., auristatins, maytansinoids), DNA-damaging agents (e.g., calicheamicin), and topoisomerase I inhibitors (e.g., deruxtecan).
 - Payload - Radioisotopes:** Incorporate β - or α -emitting radionuclides (e.g., yttrium-90, lutetium-177, actinium-225) to deliver localized ionizing radiation.

PATENT SEGMENTATION Overview: Main assignees by technology

Assignees	Antibody - Liquid Cancer	Antibody - Liquid Cancer - Only	Antibody - Solid Cancer	Antibody - Solid Cancer - Only	Linker - Cleavable	Linker - Uncleavable	Payload - Drugs	Payload - Radioisotopes
Pfizer	71	44	51	64	49	7	13	13
Genentech + Roche	62	42	36	66	18		66	66
AstraZeneca	36	18	56	30	29	15	13	26
Novartis	57	27	70	40	22	1	89	22
Genzyme	47	13	73	39	7		89	89
Amgen	12	11	37	36	2		76	54
Novo Nordisk	32	2	64	34	5		31	4
Novartis (non-pharmaceutical)	24		54	30	5		33	8
Novartis (pharmaceutical)	9	5	41	37	2	1	45	36
Astellera	7	2	37	32	14	1	42	19
Regeneron	19	4	27	12	24	13	31	14
AbbVie	14	1	27	19	3		36	22
Amgen (non-pharmaceutical)	26	16	18	10	15		36	33
Amgen (pharmaceutical)	10	6	32	28	1		16	33
Novartis (non-pharmaceutical)	22		35	13	2	2	30	16
Novartis (pharmaceutical)	4	3	26	25	4		22	29
Regeneron	10	4	29	23	13	2	35	14

ADC and radiolabeled-conjugate IP landscape is currently dominated by a small group of large pharmaceutical companies, with Pfizer, Genentech+Roche, AbbVie, AstraZeneca and Glaxo contributing the largest numbers of patent families across almost all segments (highly diversified portfolios reflecting the maturation of ADC technologies). Pfizer and Genentech + Roche in particular show balanced activity between liquid and solid cancer targets, consistent with late-stage clinical pipelines that still include hematologic CD20/CD33/CD38 programs while aggressively investing in HER2, TRK2, and other solid tumor antigens. AbbVie and AstraZeneca appear more skewed toward solid tumor Ab, in line with the current shift of the ADC market towards solid cancers.

Most players' IP is still built around drug payloads combined with cleavable linkers but Glaxo, Genentech, Roche, Memorial Sloan Kettering Cancer Center and the University of California stand out by their comparatively high activity on radioisotope payloads. This pattern is consistent with the renewed academic and industrial interest in radiolabeled antibodies for imaging and therapy, where only a limited number of radiolabeled-conjugates have reached routine clinical use so far and many programs are still at an exploratory stage. The presence of Bristol-Myers Squibb, Sanofi, Hengrui, Sichuan Kelun and ADC Therapeutics among the top assignees underlines the role of specialized ADC companies and Asian pharma as fast-moving challengers. Their portfolios are focused on solid-tumor Ab and drug payloads, which is in line with the development of next-generation ADCs and other immunoconjugates targeting the tumor microenvironment. Overall, the table depicts a highly competitive but still evolving field in which big pharma secure broad, composer-level coverage on ADC, while both specialized biotech and academic institutions drive differentiation in emerging radiolabeled-conjugate and next-generation payload/linker designs.




Figure 1. Main characteristics of approved ADCs. Of the 11 approved ADCs, 6 target hematological indications and 7 target solid-tumor indications. Various linker technologies have been used. These linkers are categorized as being cleavable or uncleavable. Payload color indicates drug conjugates. From "Antibody-drug conjugates come of age in oncology".
Figure 2. Technology breakdown according to the number of patent families. Note that some patent families can belong to several segments.

Excel file with all patents analyzed in the report

Useful patent database allows multi-criteria searches

SAMPLE

General information								Segmentation							
Family number	Patent number	Patent assignee	Title	Abstract	Earliest publication date	Citing patents/Forward citations	PDF link	Liquid Cancer	Liquid Cancer Only	Solid Cancer	Solid Cancer Only	Cleavable	Uncleavable	Drug	Radioisotope
100316652	CN114569739	SHANGHAI TAI TIANQING PHARMACEUTICALS	Antibody drug conjugates	The invention provides an antibody drug conjugate which specifically comprises an antibody part, an intermediate joint part and a cytotoxic drug part which are connected, the antibody part is an antibody aiming at a HER2 target spot, and the cytotoxic drug part is a camptothecin topoisomerase I inhibitor or a derivative thereof. The antibody drug conjugate can be used for preventing or treating cancers.	44715	US12168667 US12091418 US11999748 US11952384 US11814394 US11607459 US11685742	CN114569739.pdf			X	X			X	
100325901	CN114569738	SHANGHAI TAI TIANQING PHARMACEUTICALS	Antibody-conjugated drug, and intermediate and application thereof	The invention discloses an antibody coupling drug as well as an intermediate and application thereof. The antibody coupling medicine disclosed by the invention is shown as a formula III. The antibody coupling drug has good in-vitro cell activity, in-vivo anti-tumor activity, plasma stability and safety, and has a good patent medicine prospect.	44715	/	CN114569738.pdf			X	X			X	
100329941	CN114569735	SHANGHAI TAI TIANQING PHARMACEUTICALS	Linking-drug conjugate, preparation method and application	The invention discloses a linking group-drug conjugate as well as a preparation method and application thereof. The invention discloses a linking group-drug conjugate, the structural general formula of which is L4-L2-L1-D. The invention also provides an antibody coupling drug based on the linking group-drug conjugate, the structural general formula of which is Ab-(L3-L2-L1-D)x, the invention also discloses a small molecule ligand coupling drug based on the linker-drug conjugate, and the structural general formula of the small molecule ligand coupling drug is SM-L3-L2-L1-D. The antibody coupling drug and the small molecule ligand coupling drug provided by the invention have good biological activity and plasma stability, and have good targeting property and safety. Based on the novel linker-drug conjugate, wide application of various cytotoxic drugs, especially camptothecin, in the fields of ADC and SMDC can be realized, and tumor patients with drug resistance to microtubule ADC can be treated.	44715	/	CN114569735.pdf			X	X			X	
100335318	EP4289862 JP2023551721 AU2021390121 JP2023551721 EP4289862 JP2023551721 KR10-2023-0117839 AU2021390121 CA3201064 WO2022/117040 CN114573695	MABWELL BIOSCIENCE	Anti-human b7-h3 antibody and application thereof	Provided are an anti-human B7-H3 monoclonal antibody and an application thereof. By using a recombinant human B7-H3 extracellular region as an immunogen, a murine anti-human B7-H3 monoclonal antibody can be prepared by means of a hybridoma technology, and a murine anti-human B7-H3 antibody can bind to various domains of the B7-H3 extracellular region. A human-mouse chimeric antibody constructed on the basis of a murine antibody can specifically bind to B7-H3 of a cell surface. A humanized antibody prepared by means of CDRs transplantation and CDRs region mutation retains the ability to specifically bind to the human B7-H3 extracellular region and cell membrane surface B7-H3, and can be mediated for internalization by the cell membrane surface B7-H3.	44715	EP4514853 WO2023208034 WO202587323 WO2024251149 WO202407129 CN116514975B	EP4289862.pdf			X	X			X	
100391774	US1217888U IN202317044218 JP7454110 EP4257153 US20240016349 JP2023547557 EP4257153 KR10-2023-0117589 AU2020473745 BR112023010890 BR112023010890 CA3200812	FUDAN ZHANGJIANG BIO PHARM	Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof	An antibody-drug conjugate, and an intermediate thereof, a preparation method thereof, and an application thereof. Provided is an antibody-drug conjugate as represented by formula I. The compound has good targetability, has a good inhibitory effect on HER3-positive tumor cells, and has good druggability and high safety. The antibody-drug conjugate has an inhibitory effect on HER3, has an inhibitory effect on SK-BR-3 and SK-M20 cells, and also has a good inhibitory effect on at least one of ZR751, LNC-HP, NCI-H820, DVCAR-8, and HCC927 cells.	44721	/	CN114569734.pdf			X	X			X	

Patent information

Segments

SAMPLE

ORDER FORM

Cancer & Antibody Conjugates

Patent Landscape Analysis – December 2025

Ref.:KM005



SHIP TO

Name (Mr/Ms/Dr/Pr):

Job Title:

Company:

Address:

City:

State:

Postcode/Zip:

Country:

VAT ID Number for EU members:

Tel:

Email:

Date:

PAYMENT METHODS

Check

To pay your invoice using a check, please mail your check to the following address:

KnowMade S.A.R.L.
2405 route des Dolines
06902 Valbonne Sophia Antipolis
FRANCE

Money Transfer

To pay your invoice using a bank money wire transfer please contact your bank to complete this process. Here is the information that you will need to submit the payment:

Payee: KnowMade S.A.R.L.
Bank: Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France
IBAN: FR76 1460 7003 6360 6214 5695 139
BIC/SWIFT: CCBPFRPPMAR

Paypal

In order to pay your invoice via PAYPAL, you must first register at www.paypal.com. Then you can send money to the KnowMade S.A.R.L. by entering our E-mail address contact@knowmade.fr as the recipient and entering the invoice amount.

RETURN ORDER BY

E-mail: contact@knowmade.fr

Mail: KnowMade S.A.R.L., 2405 route des Dolines, 06902 Valbonne Sophia Antipolis, FRANCE

PRODUCT ORDER

€4,990 – Multi user license*

For price in dollars, please use the day's exchange rate. For French customer, add 20% for VAT.

All reports are delivered electronically in PDF format at payment reception.

**The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded. Please be aware that the report is watermarked on each page, with the name of the recipient and the organization (the name mentioned on the PO). This watermark also reaffirms that report sharing is not allowed.*

I hereby accept Knowmade's Terms and Conditions of Sale

Signature:

Terms and Conditions of Sales

SAMPLE

DEFINITIONS

“Acceptance”: Action by which the Buyer accepts the terms and conditions of sale in their entirety. It is done by signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”.

“Buyer”: Any business user (i.e. any person acting in the course of its business activities, for its business needs) entering into the following general conditions to the exclusion of consumers acting in their personal interests.

“Contracting Parties” or “Parties”: The Seller on the one hand and the Buyer on the other hand.

“Intellectual Property Rights” (“IPR”) means any rights held by the Seller in its Products, including any patents, trademarks, registered models, designs, copyrights, inventions, commercial secrets and know-how, technical information, company or trading names and any other intellectual property rights or similar in any part of the world, notwithstanding the fact that they have been registered or not and including any pending registration of one of the above mentioned rights.

“License”: For the reports and databases, 2 different licenses are proposed. The buyer has to choose one license:

1. Single user license: a single individual at the company can use the report.

2. Multi user license: The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded.

“Products”: Reports are established in PowerPoint and delivered on a PDF format and the database may include Excel files.

“Seller”: Based in Sophia Antipolis (France headquarters), Knowmade is a technology intelligence company specialized in the research and analysis of scientific and technical information. We provide patent landscapes and scientific state of the art with high added value to businesses and research laboratories. Our intelligence digests play a key role to define your innovation and development strategy.

1. SCOPE

1.1 The Contracting Parties undertake to observe the following general conditions when agreed by the Buyer and the Seller. ANY ADDITIONAL, DIFFERENT, OR CONFLICTING TERMS AND CONDITIONS IN ANY OTHER DOCUMENTS ISSUED BY THE BUYER AT ANY TIME ARE HEREBY OBJECTED TO BY THE SELLER, SHALL BE WHOLLY INAPPLICABLE TO ANY SALE MADE HEREUNDER AND SHALL NOT BE BINDING IN ANY WAY ON THE SELLER.

1.2 This agreement becomes valid and enforceable between the Contracting Parties after clear and non-equivocal consent by any duly authorized person representing the Buyer. For these purposes, the Buyer accepts these conditions of sales when signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”. This results in acceptance by the Buyer.

1.3 Orders are deemed to be accepted only upon written acceptance and confirmation by the Seller, within [7 days] from the date of order, to be sent either by email or to the Buyer’s address. In the absence of any confirmation in writing, orders shall be deemed to have been accepted.

2. MAILING OF THE PRODUCTS

2.1 Products are sent by email to the Buyer:

- within [1] month from the order for Products already released; or

- within a reasonable time for Products ordered prior to their effective release. In this case, the Seller shall use its best endeavours to inform the Buyer of an indicative release date and the evolution of the work in progress.

2.2 Some weeks prior to the release date the Seller can propose a pre-release discount to the Buyer.

The Seller shall by no means be responsible for any delay in respect of article 2.2 above, and including in cases where a new event or access to new contradictory information would require for the analyst extra time to compute or compare the data in order to enable the Seller to deliver a high quality Products.

2.3 The mailing of the Product will occur only upon payment by the Buyer, in accordance with the conditions contained in article 3.

2.4 The mailing is operated through electronic means either by email via the sales department. If the Product’s electronic delivery format is defective, the Seller undertakes to replace it at no charge to the Buyer provided that it is informed of the defective formatting within 90 days from the date of the original download or receipt of the Product.

2.5 The person receiving the Products on behalf of the Buyer shall immediately verify the quality of the Products and their conformity to the order. Any claim for apparent defects or for non-conformity shall be

sent in writing to the Seller within 8 days of receipt of the Products. For this purpose, the Buyer agrees to produce sufficient evidence of such defects.

2.6 No return of Products shall be accepted without prior information to the Seller, even in case of delayed delivery. Any Product returned to the Seller without providing prior information to the Seller as required under article 2.5 shall remain at the Buyer’s risk.

3. PRICE, INVOICING AND PAYMENT

3.1 Prices are given in the orders corresponding to each Product sold on a unit basis or corresponding to annual subscriptions. They are expressed to be inclusive of all taxes. The prices may be reevaluated from time to time. The effective price is deemed to be the one applicable at the time of the order.

3.2 Payments due by the Buyer shall be sent by cheque payable to Knowmade, PayPal or by electronic transfer to the following account:

Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France

BIC or SWIFT code: CCBPFRPPMAR

IBAN: : FR76 1460 7003 6360 6214 5695 139

To ensure the payments, the Seller reserves the right to request down payments from the Buyer. In this case, the need of down payments will be mentioned on the order.

3.3 Payment is due by the Buyer to the Seller within 30 days from invoice date, except in the case of a particular written agreement. If the Buyer fails to pay within this time and fails to contact the Seller, the latter shall be entitled to invoice interest in arrears based on the annual rate Refi of the «BCE» + 7 points, in accordance with article L. 441-6 of the French Commercial Code. Our publications (report, database, tool...) are delivered only after reception of the payment.

3.4 In the event of termination of the contract, or of misconduct, during the contract, the Seller will have the right to invoice at the stage in progress, and to take legal action for damages.

4. LIABILITIES

4.1 The Buyer or any other individual or legal person acting on its behalf, being a business user buying the Products for its business activities, shall be solely responsible for choosing the Products and for the use and interpretations he makes of the documents it purchases, of the results he obtains, and of the advice and acts it deduces thereof.

4.2 The Seller shall only be liable for (i) direct and (ii) foreseeable pecuniary loss, caused by the Products or arising from a material breach of this agreement

4.3 In no event shall the Seller be liable for:

a) damages of any kind, including without limitation, incidental or consequential damages (including, but not limited to, damages for loss of profits, business interruption and loss of programs or information) arising out of the use of or inability to use the Seller’s website or the Products, or any information provided on the website, or in the Products;

b) any claim attributable to errors, omissions or other inaccuracies in the Product or interpretations thereof.

4.4 All the information contained in the Products has been obtained from sources believed to be reliable. The Seller does not warrant the accuracy, completeness adequacy or reliability of such information, which cannot be guaranteed to be free from errors.

4.5 All the Products that the Seller sells may, upon prior notice to the Buyer from time to time be modified by or substituted with similar Products meeting the needs of the Buyer. This modification shall not lead to the liability of the Seller, provided that the Seller ensures the substituted Product is similar to the Product initially ordered.

4.6 In the case where, after inspection, it is acknowledged that the Products contain defects, the Seller undertakes to replace the defective products as far as the supplies allow and without indemnities or compensation of any kind for labor costs, delays, loss caused or any other reason. The replacement is guaranteed for a maximum of two months starting from the delivery date. Any replacement is excluded for any event as set out in article 5 below.

4.7 The deadlines that the Seller is asked to state for the mailing of the Products are given for information only and are not guaranteed. If such deadlines are not met, it shall not lead to any damages or cancellation of the orders, except for non-acceptable delays exceeding [4] months from the stated deadline, without information from the Seller. In such case only, the Buyer shall be entitled to ask for a reimbursement of its first down payment to the exclusion of any further damages.

4.8 The Seller does not make any warranties, express or implied, including, without limitation, those of

saleability and fitness for a particular purpose, with respect to the Products. Although the Seller shall take reasonable steps to screen Products for infection of viruses, worms, Trojan horses or other codes containing contaminating or destructive properties before making the Products available, the Seller cannot guarantee that any Product will be free from infection.

5. FORCE MAJEURE

The Seller shall not be liable for any delay in performance directly or indirectly caused by or resulting from acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, late deliveries by suppliers or other difficulties which are beyond the control, and not the fault of the Seller.

6. PROTECTION OF THE SELLER’S intellectual property

6.1 All intellectual property rights attached to the Products are and remain the property of the Seller and are protected under French and international copyright law and conventions.

6.2 The Buyer agreed not to disclose, copy, reproduce, redistribute, resell or publish the Product, or any part of it to any other party other than employees of its company. The Buyer shall have the right to use the Products solely for its own internal information purposes. In particular, the Buyer shall therefore not use the Product for purposes such as:

- Information storage and retrieval systems;

- Recordings and re-transmittals over any network (including any local area network);

- use in any timesharing, service bureau, bulletin board or similar arrangement or public display;

- Posting any Product to any other online service (including bulletin boards or the Internet);

- Licensing, leasing, selling, offering for sale or assigning the Product.

6.3 The Buyer shall be solely responsible towards the Seller of all infringements of this obligation, whether this infringement comes from its employees or any person to whom the Buyer has sent the Products and shall personally take care of any related proceedings, and the Buyer shall bear related financial consequences in their entirety.

6.4 The Buyer shall define within its company point of contact for the needs of the contract. This person will be the recipient of each new report in PDF format. This person shall also be responsible for respect of the copyrights and will guaranty that the Products are not disseminated out of the company.

7. TERMINATION

7.1 If the Buyer cancels the order in whole or in part or postpones the date of mailing, the Buyer shall indemnify the Seller for the entire costs that have been incurred as at the date of notification by the Buyer of such delay or cancellation. This may also apply for any other direct or indirect consequential loss that may be borne by the Seller, following this decision.

7.2 In the event of breach by one Party under these conditions or the order, the non-breaching Party may send a notification to the other by recorded delivery letter upon which, after a period of thirty (30) days without solving the problem, the non-breaching Party shall be entitled to terminate all the pending orders, without being liable for any compensation.

8. MISCELLANEOUS

All the provisions of these Terms and Conditions are for the benefit of the Seller itself, but also for its licensors, employees and agents. Each of them is entitled to assert and enforce those provisions against the Buyer.

Any notices under these Terms and Conditions shall be given in writing. They shall be effective upon receipt by the other Party.

The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have accepted the latest version of these terms and conditions, provided they have been communicated to him in due time.

9. GOVERNING LAW AND JURISDICTION

9.1 Any dispute arising out or linked to these Terms and Conditions or to any contract (orders) entered into in application of these Terms and Conditions shall be settled by the French Commercial Courts of Grasse, which shall have exclusive jurisdiction upon such issues.

9.2 French law shall govern the relation between the Buyer and the Seller, in accordance with these Terms and Conditions.

SAMPLE



KNOWMADE

Company presentation

KNOWMADE PURPOSE

SAMPLE

Turning **patent information** and **scientific literature** into actionable insights, providing high value-added reports for **decision-makers** working in **R&D, Intellectual Property, Innovation Strategy, and Marketing**

Competitive landscape | Technology trends | Opportunities / Risks | R&D and IP strategy



CUSTOM SERVICES

(Tailor-made analysis)

To meet your needs and budget/lead time constraints

- Specific and dedicated report.
- Prior-art search, literature review, patent landscape, freedom-to-operate, patent valuation, IP due diligence, technology scouting, monitoring service, etc.

Format

- PDF file with analyses.
- Excel file with data.
- Access to the analyst.

REPORTS

(multi-client product)

To understand the competitive landscape and explore the emerging ecosystems and new technologies

- Stand alone report
- Patent landscape.
- Overview on IP dynamics, trends and players.
- Competitor, technology and strategy analysis.
- Benchmark of patent portfolios.
- Key IP players & key patents.

Format

- PDF file with analyses.
- Excel file with patent data.

MONITORS

(multi-client product)

To track the latest R&D developments and IP activities, and to be sensitive to weak signals

- Annual subscription
- Patent monitoring service.
- Quarterly updated patent data and technology trends.
- Current R&D and IP activities.
- Early detect weak signals, opportunities and risks.
- Open discussion with analyst.

Format

- PDF file with analyses.
- Excel file with patent data.
- Direct access to the analyst.

INSIGHTS

(free article & webinar)

To get unique information about industry and technology

- Analyst point of view about industry news (product release, M&A, start-up, fund-raising, etc.) from a patent perspective.

Format

- Knowmade website

MAIN FIELDS OF EXPERTISE

SEMICONDUCTORS

- Materials & Substrates
- Power electronics
- RF & Wireless datacom
- MEMS, Sensing & Imaging
- Photonics, Lighting & Display
- Memory
- Packaging

ENERGY

- Batteries
- Fuel-cells
- Solar PV
- Power management



HEALTHCARE

- New therapeutic tools
- Medical diagnostics
- Medical devices and imaging
- Drug discovery and delivery

AGRI-FOOD

- Food processing & formulation
- Vegan food
- Next-gen packaging
- Microbiology

SAMPLE



www.knowmade.com

contact@knowmade.fr

KnowMade S.A.R.L., 2405 route des Dolines, 06902 Sophia Antipolis, France